RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/a-2741-9575
Synthesis, Anticancer Screening, and Virtual Analysis of 5-S-Substituted Derivatives of 1,3-Oxazol-4-ylphosphonates and 1,3-Oxazole-4-carbonitriles
Autoren
This work was supported by the National Academy of Sciences of Ukraine under Grants of the NAS of Ukraine to research groups of young scientists of the NAS of Ukraine in 2025-2026 ‘Design, synthesis, in silico and in vitro studies of azole derivatives as potential anticancer agents’ (Contract No. 21/02-2025(6) from 03.03.2025).
Abstract
Ten 5-(arylsulfanyl), 5-(arylsulfinyl), and 5-(arylsulfonyl) derivatives of 1,3-oxazol-4-ylphosphonates and 1,3-oxazole-4-carbonitriles were synthesized and characterized using IR, 1H NMR, 13C NMR, 31P NMR spectroscopy, elemental analysis, and mass spectrometry. Their anticancer activity was assessed against NCI-60 human tumor cell lines using a single-dose assay. Diethyl [2-phenyl-5-(phenylsulfonyl)-1,3-oxazol-4-yl]phosphonate, diethyl [5-(4-chlorophenylsulfonyl)-2-(4-methylphenyl)-1,3-oxazol-4-yl]phosphonate, and 5-(4-methylphenylsulfonyl)-2-phenyl-1,3-oxazole-4-carbonitrile, which demonstrated the highest anticancer activity, were selected for five-dose screening. The two phosphonates showed selectivity (SIr > 3 by TGI and LC50) against most leukemia lines, while the 1,3-oxazole-4-carbonitrile derivative was selective against renal (63%), colon (57%), and breast cancer (50%). One compound demonstrated selectivity against the entire leukemia subpanel. A comparison analysis revealed that no standard drug exhibited a high degree of similarity to compounds across all potency vectors. This suggests that the molecular mechanisms may be unique. Possible targets such as cannabinoid receptor 2, adenosine A3 receptor, and cyclin-dependent kinase 2 have been proposed based on in silico studies. The parameters of druglikeness predicted by the ADMET analysis were within the rational range for all compounds. The two phosphonates are expected to be preferable for the development of antileukemia agents, while 5-(4-methylphenylsulfonyl)-2-phenyl-1,3-oxazole-4-carbonitrile is considered promising for agents targeting renal, colon, and breast cancers.
Key words
1,3-oxazol-4-ylphosphonates - 1,3-oxazole-4-carbonitriles - synthesis - anticancer screening - COMPARE correlation - ADMET analysis - dockingSupporting Information
- Supporting information for this article is available online at https://doi.org/10.1055/a-2741-9575.
- Supporting Information (PDF) (opens in new window)
Publikationsverlauf
Eingereicht: 01. September 2025
Angenommen nach Revision: 07. November 2025
Accepted Manuscript online:
07. November 2025
Artikel online veröffentlicht:
01. Dezember 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Kakkar S, Narasimhan B. BMC Chem. 2019; 13: 16
- 2 Joshi S, Mehra M, Singh R, Kakar S. Egypt. J. Basic Appl. Sci. 2023; 10: 218
- 3 Yan X, Jing W, Zhou L, Fan L, Wang X, Xu Z. Curr. Top. Med. Chem. 2020; 20: 1916
- 4 Sawant RS, Deventhiran P, Uppalwar SV, Sen AK. IJRPR 2024; 5: 1510
- 5 Kulkarni S, Kaur K, Jaitak V. Anti-cancer Agents Med. Chem. 2022; 22: 1859
- 6 El-Dydamony NM, Abdelnaby RM, Abdelhady R, Ali O, Fahmy MI, Eldeen R FakhrR, Helwa AA. J. Enzyme Inhib. Med. Chem. 2022; 37: 895
- 7 Reda N, Mohamed KO, Abdou K, Helwa AA, Elshewy A. Bioorg. Chem. 2024; 145: 107185
- 8 Al-Wahaibi LH, Abou-Zied HA, Hisham M, Beshr EA. M, Youssif BG. M, Bräse S, Hayallah AM, Abdel-Aziz M. Molecules 2023; 28: 6586
- 9 Saffari Z, Aryapour H, Akbarzadeh A, Foroumadi A, Jafari N, Farahnak Zarabi M, Farhangi A. Tumour Biol. 2014; 35: 5845
- 10 Ahmed NM, Mohamed MS, Awad SM, Abd El-Hameed RH, El-Tawab NA. A, Gaballah MS, Said AM. J. Enzyme Inhib. Med. Chem. 2024; 39: 2304625
- 11 Kachaeva MV, Pilyo SG, Demydchuk BA, Prokopenko VM, Zhirnov VV, Brovarets VS. Int. J. Curr. Res. 2018; 10: 69410
- 12 Kachaeva MV, Pilyo SG, Zhirnov VV, Brovarets VS. Med. Chem. Res. 2019; 28: 71
- 13 Severin O, Pilyo S, Kachaeva M, Zhirnov V, Hodyna D, Bahrieieva O, Brovarets V. ChemMedChem 2024; 19: e202300527
- 14 Severin O, Pilyo S, Semenyuta I, Kachaeva M, Zhirnov V, Brovarets V. Curr. Chem. Lett. 2025; 14: 159
- 15 Schole J, Schole C, Eikemeyer J. Z. Naturforsch., C 1994; 49: 657
- 16 Paradies G, Paradies V, Ruggiero FM, Petrosillo G. Cells 2019; 8: 728
- 17 Kenny TC, Birsoy K. Cold Spring Harbor Perspect. Med. 2024; 14: a041534
- 18 Brusnakov M, Golovchenko O, Velihina Y, Liavynets O, Zhirnov V, Brovarets V. ChemMedChem 2022; 17: e202200319
- 19 Kondratyuk KM, Lukashuk EI, Golovchenko AV, Vasilenko AN, Brovarets VS. Russ. J. Gen. Chem. 2013; 83: 46
- 20 Pil’o SG, Brovarets VS, Vinogradova TK, Golovchenko AV, Drach BS. Russ. J. Gen. Chem. 2002; 72: 1714
- 21 Kachaeva MV, Hodyna M, Obernikhina NV, Pilyo SG, Kovalenko YS, Prokopenko VM, Kachkovsky OD, Brovarets VS. J. Heterocycl. Chem. 2019; 56: 3122
- 22 Obernikhina NV. OMCIJ 2019; 9: 555751
- 23a Lukovits I, Linert W. J. Chem. Inf. Comput. Sci. 1998; 38: 715
- 23b Chen L, Li T, Liu J, Shi Y, Wang H. PLoS One 2016; 11: e0167075
- 24 Whitley DC. J. Math. Chem. 1998; 23: 377
- 25 Agoni C, Olotu FA, Ramharack P, Soliman ME. J. Mol. Model. 2020; 26: 120
- 26 Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, Casellas P. Eur. J. Biochem. 1993; 214: 173
- 27 Soto-Mercado V, Mendivil-Perez M, Jimenez-Del-Rio M, Fox JE, Velez-Pardo C. Leuk. Res. 2020; 95: 106389
- 28 Melén CM, Merrien M, Wasik AM, Panagiotidis G, Beck O, Sonnevi K, Junlén HR, Christensson B, Sander B, Wahlin BE. Leuk. Lymphoma 2022; 63: 1387
- 29 Zhang W, Zhang C, Liu F, Mao Y, Xu W, Fan T, Sun Q, He S, Chen Y, Guo W, Tan Y, Jiang Y. Sci. Rep. 2018; 8: 15753
- 30 Fishman P, Jacobson KA, Ochaion A, Cohen S, Bar-Yehuda S. Immunol., Endocr. Metab. Agents Med. Chem. 2007; 7: 298
- 31 Peerzada MN, Dar MS, Verma S. Expert Opin. Ther. Pat. 2023; 33: 797
- 32 Maji L, Teli G, Raghavendra NM, Sengupta S, Pal R, Ghara A, Matada GS. P. Mol. Diversity 2024; 28: 2689
- 33 Marak BN, Dowarah J, Khiangte L, Singh VP. Eur. J. Med. Chem. 2020; 203: 112571
- 34 Lee K, Jang J, Seo S, Lim J, Kim WY. Chem. Sci. 2021; 13: 554
- 35 Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, Yin M, Zeng X, Wu C, Lu A, Chen X, Hou T, Cao D. Nucleic Acids Res. 2021; 49: W5
- 36 Patel D, Sethi N, Patel P, Shah S, Patel K. Eur. J. Pharm. Biopharm. 2024; 198: 114267
- 37 Gonçalves BM. F, Cardoso DS. P, Ferreira MJ. U. Molecules 2020; 25: 3364
- 38 Elfadadny A, El-Husseiny HM, Abugomaa A, Ragab RF, Mady EA, Aboubakr M, Samir H, Mandour AS, El-Mleeh A, El-Far AH, Abd El-AzizA. H, Elbadawy M. Environ. Sci. Pollut. Res. Int. 2021; 28: 49447
- 39 Husain A, Makadia V, Valicherla GR, Riyazuddin M, Gayen JR. Drug Dev. Res. 2022; 83: 825
- 40 Tian Y, Lei Y, Wang Y, Lai J, Wang J, Xia F. Int. J. Oncol. 2023; 63: 119
- 41 Guengerich FP. Annu. Rev. Pharmacol. Toxicol. 1999; 39: 1
- 42 Grever MR, Schepartz SA, Chabner BA. Semin. Oncol. 1992; 19: 622
- 43 Boyd MR, Paull KD. Drug Dev. Res. 1995; 34: 91
- 44 Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Jangley J, Cronisie P, Viagro-Wolff A, Gray-Goodrich M, Campell H, Boyd M. J. Natl. Cancer Inst. 1991; 83: 757
- 45 Data (accessed Nov 21, 2025): https://dtp.cancer.gov/discovery_development/nci-60/default.htm
- 46 Acton EM, Narayanan VL, Risbood PA, Shoemaker RH, Vistica DT, Boyd MR. J. Med. Chem. 1994; 37: 2185
- 47 Weerapreeyakul N, Nonpunya A, Barusrux S, Thitimetharoch T, Sripanidkulchai B. Chin. Med. 2012; 7: 15
- 48 History of the NCI-60 screen and COMPARE algorithm (accessed Nov 21, 2025): https://dtp.cancer.gov/databases_tools/compare.htm
- 49 Shoemaker RH. Nat. Rev. Cancer. 2006; 6: 813
- 50 Daina A, Michielin O, Zoete V. Nucleic Acids Res. 2019; 47: W357
- 51 Semenyuta I, Kovalishyn V, Tanchuk V, Pilyo S, Zyabrev V, Blagodatnyy V, Trokhimenko O, Brovarets V, Metelytsia L. Comput. Biol. Chem. 2016; 65: 8
- 52 Kachaeva MV, Hodyna DM, Semenyuta IV, Pilyo SG, Prokopenko VM, Kovalishyn VV, Metelytsia LO, Brovarets VS. Comput. Biol. Chem. 2018; 74: 294
- 53 Xing C, Zhuang Y, Xu TH, Feng Z, Zhou XE, Chen M, Wang L, Meng X, Xue Y, Wang J, Liu H, McGuire TF, Zhao G, Melcher K, Zhang C, Xu HE, Xie XQ. Cell 2020; 180: 645
- 54 He L, Zhao Q, Qi J, Wang Y, Han W, Chen Z, Cong Y, Wang S. Proc. Natl. Acad. Sci. U. S. A. 2023; 120: e2209917120
- 55 Cai H, Guo S, Xu Y, Sun J, Li J, Xia Z, Jiang Y, Xie X, Xu HE. Nat. Commun. 2024; 15: 3252
- 56 Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M. Nature 2004; 428: 198
- 57 Wenglowsky S, Ren L, Ahrendt KA, Laird ER, Aliagas I, Alicke B, Buckmelter AJ, Choo EF, Dinkel V, Feng B, Gloor SL, Gould SE, Gross S, Gunzner-Toste J, Hansen JD, Hatzivassiliou G, Liu B, Malesky K, Mathieu S, Newhouse B, Raddatz NJ, Ran Y, Rana S, Randolph N, Risom T, Rudolph J, Savage S, Selby LT, Shrag M, Song K, Sturgis HL, Voegtli WC, Wen Z, Willis BS, Woessner RD, Wu W, Young WB, Grina J. ACS Med. Chem. Lett. 2011; 2: 342
- 58 Betzi S, Alam R, Martin M, Lubbers DJ, Han H, Jakkaraj SR, Georg GI, Schönbrunn E. ACS Chem. Biol. 2011; 6: 492
- 59 Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. Nucleic Acids Res. 2000; 28: 235
- 60 Trott O, Olson AJ. J. Comput. Chem. 2010; 31: 455
- 61 Marvin n. n. n. (5.2.4.), 201n (2009), ChemAxon (accessed Nov 21, 2025): http://www.chemaxon.com
- 62 Hanwell MD, Curtis DE, Lonie DC. J. Cheminform. 2012; 4: 4
- 63 Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. J. Comput. Chem. 2009; 30: 2785
- 64 ADMETlab3 (accessed Nov 21, 2025): https://admetlab3.scbdd.com/server/evaluation
- 65 SwissADME (accessed Nov 21, 2025): http://www.swissadme.ch/index.php
- 66 Deep-PK deep learning for small molecule pharmacokinetic and toxicity prediction (accessed Nov 21, 2025): https://biosig.lab.uq.edu.au/deeppk/prediction
- 67 Introduction to MarvinView (accessed Nov 21, 2025): https://docs.chemaxon.com/display/lts-europium/introduction-to-marvinview.md